The most recent developments regarding therapies based on incretin hormones (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)) are likely to fundamentally change our therapy for type 2 diabetes mellitus (T2DM), obesity and conditions associated with diabetes and obesity, i
Fat tissue isn't metabolically inert storage
At Extension Health, we harness clinically validated peptide therapies to support your unique health goals, whether youre seeking enhanced recovery, improved energy, cognitive clarity, or hormonal optimization
The safest decision comes from identifying the likely cause, considering symptoms and risk factors, testing where appropriate and following a treatment plan
Full refund.
Blinding of participants and personnel was not reported in five trials, hence the risk of performance bias was considered unclear